.Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CC51_SumatriptanAndNaproxen.SumatriptanAndNaproxen .Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CC51_SumatriptanAndNaproxen.SumatriptanAndNaproxen| name: | SumatriptanAndNaproxen | |
| ATC code: | N02CC51 | route: | oral |
| compartments: | 1 | |
| dosage: | 85 | mg |
| volume of distribution: | 2.4 | L |
| clearance: | 1160 | ml/min |
| other parameters in model implementation | ||
Sumatriptan and naproxen is a fixed-dose combination medication used for the acute treatment of migraine attacks, with or without aura, in adults. Sumatriptan is a selective 5-HT1B/1D receptor agonist causing cranial vessel constriction and inhibition of neuropeptide release, while naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that reduces inflammation and pain. The combination is FDA-approved and widely used in clinical practice.
Pharmacokinetic parameters for sumatriptan and naproxen fixed combination, in healthy adult subjects, following oral administration.